How to Investigate a Disease Mechanism: A Computational Framework

Most disease research does not fail for lack of data. It fails for lack of context. A genomics experiment returns thousands of differentially expressed genes. A proteomics run surfaces hundreds of significantly changed proteins. A metabolomics dataset identifies dozens of perturbed metabolites. The standard next step? Run pathway enrichment, check the Reactome output and get a list of canonical pathways that often feels unrelated to the specific biology you were investigating. The problem is not the data. It is the framework used to interpret it. Interrogating disease mechanisms computationally is not a linear process of generating data and plugging it into a tool. It requires a structured, iterative approach that anchors statistical outputs in biological context, integrates multiple evidence layers, and builds toward mechanistic hypotheses rather than pathway lists. This article outlines that framework, with the specific steps and tools that make it work in practice.

Why Standard Pathway Enrichment Is Not Enough

Pathway enrichment analysis is one of the most widely used approaches in computational biology, and one of the most frequently misused. The approach is elegant in principle: take a list of significant genes or proteins, find which annotated pathways are statistically over-represented, and use that to interpret the biology. The problem is that multiple factors substantially affect whether the results are biologically meaningful. Research has consistently shown that pathway enrichment results are sensitive to the choice of method, the choice of database, and the statistical threshold applied. Equivalent pathways represented in different databases can yield disparate enrichment results from the same input data, and the choice of enrichment method has a comparable effect on which pathways are identified as significant. The deeper issue is biological context. Standard enrichment tools treat your gene list as a generic input against a generic knowledge base. They have no way of knowing that you are studying a specific disease in a specific cell type at a specific stage of progression. Labs working with pathway analysis routinely arrive at the conclusion that enrichment algorithms not anchored in cell-type-specific and condition-specific data have limited utility, because the same canonical pathway can be active, suppressed, or irrelevant depending on the biological context in which it is being examined. This is the starting point for a better framework: context must precede analysis, not follow it.

Step 1: Define the Biological Context Before Opening a Tool

The single most impactful change a researcher can make to their computational disease investigation is to synthesize the published literature on the specific experimental system before running any analysis. This means: what cell type are you studying, what is the known signaling landscape of that cell type in the disease context, what pathways have been shown to be active or dysregulated in prior work, and what endpoints have been previously measured? This synthesis does not need to be a formal systematic review. It needs to be specific enough to generate a prior probability map, a set of biological hypotheses against which your data will be tested. The literature synthesis step is often skipped in computational analyses because it appears qualitative. In practice, it is quantitative in effect: it determines which enrichment results are worth investigating and which are statistical noise. A pathway that returns a significant p-value and is also supported by published mechanistic evidence in your disease system is a meaningful result. A pathway that is statistically enriched but has no plausible connection to your experimental context is, absent further evidence, likely a false positive or a secondary effect. Building this synthesis rigorously across transcriptomics papers, proteomics studies, metabolomics experiments, and mechanistic cell biology work in your specific disease and cell type transforms downstream analysis from a statistical exercise into a directed scientific investigation.

Step 2: Layer the Omics Data

Once the biological context is established, the multi-omics data can be analyzed not as independent datasets but as complementary evidence for underlying biological events. Systems biology, understood as a holistic computational framework for modeling complex biological systems, is critical for leveraging multi-omics datasets to identify disease mechanisms. While the integration of high-throughput sequencing data opens new ways to unravel disease pathogenesis, the methods for connecting different omics layers to produce mechanistic insight remain an active area of development. The practical approach is to identify nodes that appear consistently across multiple omics layers. A protein whose abundance is significantly changed, whose encoding gene is differentially expressed, and whose downstream metabolic products are measurably altered represents a much stronger mechanistic signal than a single-omics hit. Conversely, a gene that is transcriptionally upregulated but unchanged at the protein level is not a failure to replicate. It is biologically informative. Transcript and protein levels are frequently discordant, and this discordance is largely of biological rather than technical origin. It represents a critical layer of post-transcriptional regulation that is routinely neglected when analyses treat transcriptomic data as a proxy for the proteome. Understanding where and why this discordance occurs in a disease context is itself mechanistically informative. It points to translational regulation, RNA-binding protein activity, protein degradation, or compartmentalization as active regulatory layers in the system under study. This means that in a multi-omics disease investigation, discordant results between data layers are not problems to be resolved. They are hypotheses to be investigated.

Step 3: Move From Pathways to Cascades

Standard pathway enrichment maps data onto static, annotated pathway objects. A disease mechanism is rarely a single pathway. It is a cascade of events: a receptor activation triggering a kinase, which phosphorylates a transcription factor, which drives expression of a metabolic enzyme, whose substrate accumulates and acts as a second messenger affecting a downstream target. Reconstructing that cascade from multi-omics data requires working at the level of individual molecular interactions, not pathway annotations. The practical approach here is to use the significant hits from the multi-omics analysis as anchor nodes and expand outward using known protein-protein interaction networks, signaling databases such as SIGNOR or OmniPath, and the published mechanistic literature. For each anchor, a significantly changed kinase, phosphatase, or transcription factor, the question is: what does the published evidence say this protein activates or inhibits downstream, and are any of those downstream effectors also present and changed in the data? Frameworks that link key molecules highlighted from broad omics data analysis and computational modeling to dysregulated pathways in a cell-, tissue-, or patient-specific manner represent a significant step forward over generic pathway enrichment. By combining multi-omics data analysis with mechanistic disease maps and computational modeling, researchers can trace causal interactions and identify which molecular events are driving observed phenotypes rather than accompanying them. This cascade reconstruction step produces candidate mechanisms rather than pathway lists. Each candidate mechanism should be documentable as a chain of molecular events with at least one published study supporting each link in the chain.

Step 4: Distinguish Drivers From Passengers

A persistent challenge in disease mechanism investigation is that most differentially expressed genes and proteins in a disease state are passengers, not drivers. They change because something upstream of them changed, not because they are causally relevant to the disease phenotype. Distinguishing drivers from passengers requires integrating genetic evidence with the functional data. Genetic variants associated with disease through GWAS or sequencing studies, particularly those affecting protein-coding sequence or known regulatory regions, provide independent evidence for causality that functional omics data alone cannot. A protein whose gene carries a disease-associated variant, whose abundance is changed in disease tissue, and which sits upstream of a cascade involving other changed proteins, is a candidate driver. A protein that is highly differentially expressed but genetically unassociated with the disease is more likely a passenger or a reactive change. This integration of genetic and functional evidence is the basis of Mendelian randomization approaches and colocalization analyses, which have become increasingly central to disease mechanism investigation over the past decade. The underlying logic is straightforward: genetic variants are fixed at conception, so if a variant affects the level of a protein and that variant is also associated with disease risk, the most parsimonious explanation is that the protein causally contributes to disease.

Step 5: Use Contradiction as a Directional Signal

Any multi-omics disease dataset will contain results that appear contradictory across evidence layers. A canonical inflammatory pathway appears suppressed in the transcriptomics but activated based on protein phosphorylation data. A metabolite accumulates despite the enzyme responsible for producing it being downregulated. Contradictions of this kind are the most scientifically valuable outputs of a multi-omics analysis, precisely because they point to regulatory biology that the standard single-layer analysis would have missed entirely. The approach to a contradiction is not to average across the layers or to prioritize one data type over another by default. It is to ask what mechanism would produce this specific discordance in this specific biological system. The answer may be post-transcriptional regulation, enzyme allosteric activation, substrate channeling, protein isoform switching, subcellular compartmentalization, or a feedback loop operating on a different timescale than the measurement captured. Integrating multi-omics data combined with systems biology approaches and orthogonal experimental validation enables researchers to elucidate the intricate interactions between genetic and epigenetic alterations, organelle dysfunction, and dysregulated signaling pathways in a way that goes beyond descriptive analysis toward mechanistic understanding. Each contradiction, properly investigated, narrows the hypothesis space for what the disease mechanism is and generates a testable prediction for experimental validation.

Step 6: Generate and Rank Mechanistic Hypotheses

The output of a rigorous computational disease mechanism investigation is not a list of significant genes, enriched pathways, or candidate biomarkers. It is a ranked set of mechanistic hypotheses, each of which states a specific causal chain connecting a molecular event to a disease phenotype, supported by converging evidence from multiple data layers and the published literature, and falsifiable by a defined experimental approach. A well-formed mechanistic hypothesis looks like this: treatment X activates receptor Y in cell type Z, which phosphorylates kinase A, which promotes the transcription of enzyme B, whose product C accumulates and allosterically inhibits pathway D, explaining the observed suppression of D in both the transcriptomic and metabolomic data despite no change in D's own expression. Each step in this chain is supported by at least one published study and at least one piece of evidence from the experimental data. The hypothesis makes a prediction, that inhibiting kinase A should prevent the accumulation of metabolite C, which can be tested before committing resources to a larger experimental campaign. Generating hypotheses at this level of specificity requires holding the experimental data and the published mechanistic literature simultaneously, and reasoning across both in a structured way. This is precisely where the scale of modern disease research makes manual analysis insufficient: omics approaches, particularly those with single-cell and spatial resolution, provide unique opportunities to study the deregulation of intra- and inter-cellular processes in disease, but extracting mechanistic information from these datasets requires computational methods that can integrate the data with existing biological knowledge in a systematic and context-specific way.

The Role of Context-Aware AI in Disease Mechanism Research

The framework described above is not new in its individual components. Experienced computational biologists have worked this way for years. What has changed is the scale: the volume of published literature, the size of multi-omics datasets, and the number of known molecular interactions have all grown to a point where manual synthesis across all relevant evidence is no longer tractable. Context-aware AI tools that can synthesize the literature for a specific disease and cell type, connect that synthesis to a researcher's own data, trace molecular cascades across known interaction databases, and generate ranked mechanistic hypotheses represent a genuine shift in the capacity of individual research groups to investigate disease biology at the depth this framework requires. The scientific logic of the framework does not change. The throughput does. What matters is that the AI operates within a research context, not as a generic search layer. A literature synthesis about pathway dysregulation in general is not useful. A synthesis about the specific regulatory mechanisms controlling a specific kinase in the specific cell type and disease condition being studied, connected to the experimental data from that study, is the beginning of a mechanistic investigation. That is the standard this kind of work should be held to, and the one a serious computational disease research framework is built around.

References

Zhang Y, Thomas JP, Korcsmaros T, Gul L. Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease. Cell Reports Medicine. 2024;5(9):101738.https://pubmed.ncbi.nlm.nih.gov/39293401/
Niarakis A et al. A versatile and interoperable computational framework for the analysis and modeling of COVID-19 disease mechanisms. Frontiers in Bioinformatics. 2024.https://pmc.ncbi.nlm.nih.gov/articles/PMC10897000
Mubeen S et al. The impact of pathway database choice on statistical enrichment analysis and predictive modeling. Frontiers in Genetics. 2019.https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.01203
Nguyen TM, Shafi A, Nguyen T, Draghici S. On the influence of several factors on pathway enrichment analysis. Briefings in Bioinformatics. 2022.https://pmc.ncbi.nlm.nih.gov/articles/PMC9116215/
Culjkovic-Kraljacic B, Borden KLB. The impact of post-transcriptional control: better living through regulation. Frontiers in Genetics. 2018.https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2018.00512
Wallace EWJ et al. Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy. eLife. 2021.https://pmc.ncbi.nlm.nih.gov/articles/PMC6349399
Frontiers in Molecular Biosciences Research Topic: Integrative Omics for Insights into Human Disease Mechanisms and Therapeutic Potentials. 2025.https://www.frontiersin.org/research-topics/71658
Saez-Rodriguez J. Knowledge-based machine learning to extract disease mechanisms from multi-omics data. EMBL-EBI Seminar Series. 2025.https://www.babraham.ac.uk/seminars/2025/04/knowledge-based-machine-learning-extract-disease-mechanisms-multi-omics-data

How to Investigate a Disease Mechanism: A Computational Framework